You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Israel signs deal with Pfizer for potential 8 mn doses of Covid-19 vaccine

Pfizer's potential vaccine is likely to be a two-dose course of treatment

Topics
Coronavirus Tests | Coronavirus Vaccine | Community Transmission

Reuters  |  TEL AVIV 

Photo courtesy: Reuters
Photo courtesy: Reuters

TEL AVIV (Reuters) - signed a deal with Inc on Friday to receive 8 million doses of the drugmaker's potential COVID-19 vaccine, Prime Minister Benjamin Netanyahu said, enough to cover close to half of Israel's population.

and German partner BioNTech SE confirmed a deal was forthcoming in a statement on Thursday but did not disclose financial details. There was no immediate comment from the two companies on Friday.

The agreement still requires approval by the U.S. Food and Drug Administration (FDA) and Israel's health ministry, Israeli Health Minister Yuli Edelstein said. is expected to apply for approval this month, he added.

Pfizer's potential vaccine is likely to be a two-dose course of treatment, meaning that 8 million doses would cover 4 million of Israel's 9 million population.

In televised remarks, Netanyahu said the agreement marked "a great day for Israel" and added: "The goal is for the vaccine supply to start in January and increase in the months thereafter".

Pfizer on Monday announced that its experimental COVID-19 vaccine was more than 90% effective based on initial trial results, a potential major victory in the war against a virus that has killed more than a million people and battered the world economy.

In addition to its new deal with Pfizer, has an agreement with Moderna Inc for the future purchase of its potential vaccine. Moderna said on Wednesday it had enough data for a first interim analysis of the late-stage trial of its vaccine candidate.

 

(Reporting by Rami Ayyub. Editing by Jane Merriman)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 13 2020. 19:36 IST
RECOMMENDED FOR YOU